The abstract is read at the publisher; the summary is JClub's.
NZEP TA-Ce, a nanozyme-exoskeletonized yeast-derived polysaccharide, inhibits MAPK and NF-κB inflammatory signaling in mice and improves inflamed-colon retention and barrier repair.
- Why it matters: Inflammatory bowel disease often co-occurs with anxiety and depression, and existing therapies do not fully address the linked inflammatory, barrier, and microbiota disturbances driving these comorbidities.
- What they did: The team engineered nanozyme-exoskeletonized yeast-derived polysaccharides (NZEP) using an insect sclerotization-inspired integration strategy, then tested oral NZEP TA-Ce in a mouse IBD model for colonic localization, inflammatory signaling, barrier repair, and microbiota/metabolite changes.
- The result: In mice, NZEP TA-Ce reverses gut microbiota dysbiosis and normalizes microbial metabolites, which is linked to alleviation of anxiety and depressive symptoms associated with IBD.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.